Graduate Institute of Clinical Medicine

Medicine & Life Sciences

1. Apoptosis 20%
2. Arsenic 17%
3. Atrial Fibrillation 18%
4. Autophagy 11%
5. Biomarkers 14%
6. Bipolar Disorder 15%
7. Blood Pressure 8%
8. Bone and Bones 7%
9. Breast Neoplasms 17%
10. Calcium 11%
11. Carcinoma 9%
12. Cardiac Myocytes 13%
13. Cardiovascular Diseases 7%
14. Case-Control Studies 8%
15. Catenins 9%
16. Cell Line 8%
17. Cell Movement 8%
18. Cell Proliferation 8%
19. Chronic Kidney Failure 7%
20. Chronic Obstructive Pulmonary Disease 10%
21. Chronic Renal Insufficiency 22%
22. Cohort Studies 28%
23. Colonic Neoplasms 7%
24. Colorectal Neoplasms 15%
25. Confidence Intervals 26%
26. Databases 12%
27. Dementia 7%
28. Depression 7%
29. Diabetes Mellitus 7%
30. Dialysis 8%
31. Down-Regulation 14%
32. Drug Therapy 9%
33. Endothelial Cells 8%
34. Epithelial-Mesenchymal Transition 8%
35. ErbB Receptors 8%
36. Fibroblasts 7%
37. Fibrosis 8%
38. Gene Expression 10%
39. Genes 17%
40. Glioblastoma 7%
41. Growth 11%
42. Heart Failure 6%
43. Heme Oxygenase-1 8%
44. Hepatocellular Carcinoma 17%
45. Hyperoxia 8%
46. Hypertension 8%
47. In Vitro Techniques 11%
48. Incidence 12%
49. Inflammation 11%
50. Kidney 17%
51. Lipopolysaccharides 8%
52. Liver 7%
53. Logistic Models 6%
54. Lung 12%
55. Lung Neoplasms 11%
56. Macrophages 8%
57. Mesenchymal Stem Cells 8%
58. Messenger RNA 7%
59. Meta-Analysis 35%
60. Metabolic Syndrome 8%
61. Methylation 9%
62. MicroRNAs 10%
63. Mortality 16%
64. Mouth Neoplasms 7%
65. Mutation 7%
66. National Health Programs 11%
67. Neoplasm Metastasis 17%
68. Neoplasms 34%
69. Neoplastic Stem Cells 10%
70. Nitric Oxide 8%
71. Non-Small Cell Lung Carcinoma 9%
72. Odds Ratio 18%
73. Ovarian Neoplasms 7%
74. Oxidative Stress 8%
75. Peroxisome Proliferator-Activated Receptors 8%
76. Pharmaceutical Preparations 7%
77. Pneumonia 7%
78. Population 28%
79. Prostatic Neoplasms 9%
80. Proteins 14%
81. Pulmonary Veins 18%
82. Quality of Life 7%
83. Randomized Controlled Trials 20%
84. Reactive Oxygen Species 12%
85. Recurrence 8%
86. Renal Dialysis 14%
87. Retrospective Studies 8%
88. Safety 7%
89. Schizophrenia 11%
90. Serum 11%
91. Skin 7%
92. Sleep 9%
93. Stroke 30%
94. Survival 10%
95. Systematic Reviews 20%
96. Taiwan 100%
97. Therapeutics 23%
98. Triple Negative Breast Neoplasms 7%
99. Up-Regulation 9%
100. Wounds and Injuries 11%